

ECI830

Chemical Properties


CAS No. : 3054692-62-2

Formula: C₁₉H₂₄N₆O₃

Molecular Weight: 384.43

Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year

Actual storage temperature shall be subject to the COA.



Biological Description

Description	ECI830 is a highly potent and selective oral small-molecule CDK2 inhibitor. ECI830 inhibits CDK2 activity and induces G1/S phase cell cycle arrest, thereby blocking DNA replication and tumor proliferation. ECI830 is suitable for research in HR+/HER2- breast cancer models and tumor systems with CCNE1 amplification, particularly in studies of CDK2-dependent cell-cycle regulation and proliferative signaling networks.
Targets(IC50)	CDK
In vitro	Methods:CCNE1-amplified ovarian cancer OVCAR3 cells and lung cancer H810 cells were selected to evaluate the in vitro antiproliferative effect of ECI830. Results:ECI830 exerted prominent antiproliferative activity against CCNE1-amplified ovarian and lung cancer cells [1].
In vivo	Methods:A xenograft model of drug-resistant HR+/HER2 breast cancer MCF7 cells was established. Monotherapy with ECI830 or ribociclib and combined medication were applied respectively. Signaling pathway activity, biomarker expression and tumor growth were compared among groups. Results:Combined treatment exerted synergistic efficacy compared with single drugs, presenting stronger pathway inhibition, more obvious biomarker regulation and remarkably enhanced tumor growth suppression [1].

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	2.6013 mL	13.0063 mL	26.0125 mL
5 mM	0.5203 mL	2.6013 mL	5.2025 mL
10 mM	0.2601 mL	1.3006 mL	2.6013 mL
50 mM	0.052 mL	0.2601 mL	0.5203 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

Karin Briner, et al. Cyclin-dependent kinase (cdk2) inhibitors. Patent WO2024/171094A1.

Ophelia Maertens, et al. Abstract 3099: Selective CDK2 inhibition with ECI830: preclinical characterization, efficacy, and on-target mechanism supported by biomarker and gene signature analysis. Cancer Res (2026) 86 (7_Supplement): 3099.

Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel: 781-999-4286 E_mail: info@targetmol.com Address: 34 Washington Street, Wellesley Hills, MA 02481